Coastar Therapeutics

Biotech startup focusing on virus delivery technology


(

Private Fundraise

This company may be interested in raising funds from accredited investors. You must Request Access to see more information about this company.

Request Access 9

BIOLOGICAL PAYLOAD DELIVERED
Coastar Therapeutics:
Fast Facts

Coastar Therapeutics' revolutionary journey began in 2017. At that time, oncolytic virus therapy had gained a lot of traction, becoming an annual highlight in National Cancer Institute (NCI). But as promising as this therapy was, one of the key challenges had yet to be overcome: immune clearance of the virus. Coastar Therapeutics was then launched to overcome this tremendous issue, paving the way for superior oncolytic virus therapy in cancer patients.

BIOLOGICAL PAYLOAD DELIVERED
A Massive Problem That Demands a Solution

Oncolytic viruses are starting to come into prominence, thanks entirely to their potential to treat a broad range of cancers. Their synergistic effects with current immuno-oncology drugs only makes oncolytic viruses that much more appealing.

New therapies are not without challenges, however. One of the biggest involved in oncolytic viral therapy is the virus clearance by the immune system.

This is especially true in repeated dosings of the virus, which limits the viral therapy to only intratumoral injection to minimize immune system clearance.

BIOLOGICAL PAYLOAD DELIVERED
Coastar Therapeutics Is The Solution

Coastar Therapeutics is solving this problem with a proprietary ELCV platform that can address this issue head-on.

By coating therapeutic viruses with a layer of human cell lipid, we can conceal the virus from immune system clearance.

This will increase the overall efficacy of the treatment and allows us to:

BIOLOGICAL PAYLOAD DELIVERED
Traction & Accomplishments

Coastar has already achieved several milestones with its ELCV coating technology, including success on:

We have also received positive feedback from a number of major pharmaceutical companies, including Pfizer, Amgen, Takeda and Daiichi Sankyo). Most of the pharma giants have agreed to have a deeper discussion about our groundbreaking innovations once more data is available.

Additionally, we are proud to say that we have performed very well in various pitch competitions, ranking 6th in China and 3rd in the United States.

BIOLOGICAL PAYLOAD DELIVERED
Patents and Partnerships

BIOLOGICAL PAYLOAD DELIVERED
Meet The Team

Eddie Chung
FOUNDER AND CEO

  • 10+ years of experience in the field of nanoparticle design, formulation and process development
  • Has led several projects and helped several biotech companies reach their seed stage and series A milestones
  • Received his MS degree in UCSD bioengineering and BS degree in National Tsinghua University biomedical engineering

Han L Lim
CO-FOUNDER AND CSO

  • Dr. Lim has worked on many interdisciplinary projects focusing on integrating synthetic or biological materials with cells to engineer tissue from the micro- to macro-scale
  • He has helped his previous company grow and receive several funding from grants to private investments
  • Dr. Lim received his PhD degree from UCSD Bioengineering

BIOLOGICAL PAYLOAD DELIVERED
​Scientific Advisors

Joseph Glorioso III, PhD

PROFESSOR OF UNIV. OF PITTSBURGH

  • Expertise in oncolytic herpes virus
  • Founder of Oncorus

Sunil J. Advani, MD
PHYSICIAN AT MOORES CANCER CENTER

  • Research experience with oncolytic adenovirus
  • Co-investigator of a phase-1 oncolytic viral therapy
    .

Tze-Wen Chung, PhD
PROFESSOR AND FELLOW OF AIMBE

  • Fellow of American Institute for Medical and Biological Engineering
  • 30+ years of biomaterials and drug delivery experience

The Business Plan area is locked. You must Request Access to this company to see more information including the Business Plan.


Request Access

N

No updates yet.




%

No backers yet.




Quick Signup TBD

You must have an account to do this!


the startups.com platform

Copyright © 2019 Startups.com. All rights reserved.

Fundable is a software as a service crowdfunding platform. Fundable is not a registered broker-dealer and does not offer investment advice or advise on the raising of capital through securities offerings. Fundable does not recommend or otherwise suggest that any investor make an investment in a particular company, or that any company offer securities to a particular investor. Fundable takes no part in the negotiation or execution of transactions for the purchase or sale of securities, and at no time has possession of funds or securities. No securities transactions are executed or negotiated on or through the Fundable platform. Fundable receives no compensation in connection with the purchase or sale of securities.